Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 2/20 | 0.76 |
| ▸ | KIT | P10721 | 2/20 | 0.76 |
| ▸ | FLT1 | P17948 | 2/20 | 0.76 |
| ▸ | KDR | P35968 | 2/20 | 0.76 |
| ▸ | ABL2 | P42684 | 2/20 | 0.76 |
| ▸ | FLT4 | P35916 | 1/20 | 0.76 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16933054 | 1.00 | ADH1A (0.76) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL28431476 | 1.00 | ADH1A (0.76) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL20975368 | 0.88 | ADH1A (0.74) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL14137732 | 0.88 | ADH1A (0.74) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL31134843 | 0.86 | ADH1A (1.00) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL16487408 | 0.86 | ADH1A (1.00) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL16493086 | 0.86 | ADH1A (1.00) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL22300729 | 0.86 | ADH1A (1.00) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL6325853 | 0.86 | ADH1A (0.78) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL18064560 | 0.86 | ADH1A (0.57) | ADH1AKITFLT1KDRABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235387-A1 | DEVICES AND METHODS FOR GENOMIC STRUCTURAL ANALYSIS | DIMENSIONGEN (KY) | 2023-07-27 | — | — | US | disclosed |
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-3782654-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2020247976-A1 | SYSTEMS AND METHODS FOR STABILIZING EMULSIONS | DROPWORKS, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3191135-B1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH INC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20200255539-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. | 2020-08-13 | — | — | US | disclosed |
| US-10556966-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. | 2020-02-11 | — | — | US | disclosed |
| US-10544215-B2 | 1-(Chloromethyl)-2,3-dihydro-1H-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment | GENENTECH, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| CN-105636612-B | Antibody-drug conjugates and methods of use and treatment | 基因泰克公司 | 2020-01-14 | — | — | CN | disclosed |
| US-10442836-B2 | 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment | GENENTECH, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| WO-2016205176-A1 | ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| US-9518118-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160354485-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | GENENTECH, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| EP-3082876-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | Genentech, Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-3033111-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | Genentech, Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| US-20160096893-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| WO-2016040723-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2015095212-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | GENENTECH, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150165063-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | AUCKLAND CANCER SOCIETY RESEARCH CENTRE (NZ) | 2015-06-18 | — | — | US | disclosed |
| WO-2015023355-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | GENENTECH, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150165063-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | IDO1, DBI, IDO2 | ADH1A 431/4885KIT 2127/4885FLT1 1438/4885 |
| US-10556966-B2 | Anti-HER2 antibodies and immunoconjugates | ERBB2, EGFR, ERBB3 | ADH1A 4622/4885KIT 467/4885FLT1 351/4885 |
| US-20160096893-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | ERBB2, EGFR, ERBB3 | ADH1A 4622/4885KIT 467/4885FLT1 351/4885 |
| US-20200255539-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | ADH1A 4622/4885KIT 467/4885FLT1 351/4885 |
| US-10442836-B2 | 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment | IDO1, DBI, IDO2 | ADH1A 431/4885KIT 2127/4885FLT1 1438/4885 |
| US-20160354485-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | IDO1, DBI, IDO2 | ADH1A 431/4885KIT 2127/4885FLT1 1438/4885 |
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | ADH1A 4622/4885KIT 467/4885FLT1 351/4885 |
| US-10544215-B2 | 1-(Chloromethyl)-2,3-dihydro-1H-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment | IDO1, DBI, IDO2 | ADH1A 431/4885KIT 2127/4885FLT1 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.